In patients with head and neck squamous cell carcinoma refractory to platinum-based chemotherapy, those treated with nivolumab had a 30% reduction in the risk of death compared with those assigned to receive one of three single-agent chemotherapies, according to a recent phase III trial. In addition, 1-year survival among nivolumab recipients was double that of those who received a chemotherapeutic, the current standard of care.
from Cancer via ola Kala on Inoreader http://ift.tt/296vnlq
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου